6 249

Cited 36 times in

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

DC FieldValueLanguage
dc.contributor.author고형준-
dc.contributor.author노미인-
dc.contributor.author변여주-
dc.contributor.author이성철-
dc.date.accessioned2015-04-23T16:44:04Z-
dc.date.available2015-04-23T16:44:04Z-
dc.date.issued2010-
dc.identifier.issn0721-832X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101125-
dc.description.abstractPURPOSE: To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. RESULTS: Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p < 0.001). Central macular thickness decreased significantly from 491.0 microm to 255.8 microm in the IVTA group, and from 477.4 microm to 218.9 microm in the IVB group 12 months after injection (p < 0.001). In between-group comparisons, neither visual acuity (p = 0.892) nor macular thickness (p = 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p < 0.0001). CONCLUSIONS: IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group-
dc.description.statementOfResponsibilityopen-
dc.format.extent963~971-
dc.relation.isPartOfGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAngiogenesis Inhibitors/administration & dosage*-
dc.subject.MESHAntibodies, Monoclonal/administration & dosage*-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHBevacizumab-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHImmunosuppressive Agents/administration & dosage*-
dc.subject.MESHInjections, Intraocular-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMacular Edema/drug therapy*-
dc.subject.MESHMacular Edema/etiology-
dc.subject.MESHMacular Edema/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRetinal Vein Occlusion/complications-
dc.subject.MESHRetinal Vein Occlusion/drug therapy*-
dc.subject.MESHRetinal Vein Occlusion/pathology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSecondary Prevention-
dc.subject.MESHTriamcinolone Acetonide/administration & dosage*-
dc.subject.MESHVisual Acuity/drug effects-
dc.subject.MESHVitreous Body-
dc.titleIntravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학)-
dc.contributor.googleauthorYeo Jue Byun-
dc.contributor.googleauthorMi In Roh-
dc.contributor.googleauthorSung Chul Lee-
dc.contributor.googleauthorHyoung Jun Koh-
dc.identifier.doi10.1007/s00417-010-1320-2-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00152-
dc.contributor.localIdA01279-
dc.contributor.localIdA01851-
dc.contributor.localIdA02873-
dc.relation.journalcodeJ00951-
dc.identifier.eissn1435-702X-
dc.identifier.pmid20182882-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00417-010-1320-2-
dc.subject.keywordBevacizumab-
dc.subject.keywordBranch retinal vein occlusion-
dc.subject.keywordTriamcinolone acetonide-
dc.contributor.alternativeNameKoh, Hyoung Jun-
dc.contributor.alternativeNameRoh, Mi In-
dc.contributor.alternativeNameByun, Yeo Jue-
dc.contributor.alternativeNameLee, Sung Chul-
dc.contributor.affiliatedAuthorKoh, Hyoung Jun-
dc.contributor.affiliatedAuthorRoh, Mi In-
dc.contributor.affiliatedAuthorByun, Yeo Jue-
dc.contributor.affiliatedAuthorLee, Sung Chul-
dc.citation.volume248-
dc.citation.number7-
dc.citation.startPage963-
dc.citation.endPage971-
dc.identifier.bibliographicCitationGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, Vol.248(7) : 963-971, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.